Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)–related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity of vaccine clinical trial material (CTM) representat...

Full description

Bibliographic Details
Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Subjects:	Respiratory syncytial virus RSV vaccine Ad26, immunogenicity, Ad26.RSV.preF, RSV preF protein
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2383504

Similar Items

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life
by: Tessa Hosman, et al.
Published: (2024-12-01)

Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children: A Narrative Review
by: Nicola Principi, et al.
Published: (2025-07-01)

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
by: Michaela Höck, et al.
Published: (2025-10-01)

Respiratory Syncytial Virus Vaccination Acceptance: The Importance of Asking “Why?”
by: Molly Zeme, BA, et al.
Published: (2025-09-01)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
by: Freek Cox, et al.
Published: (2023-03-01)

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01)

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
by: Bryony Treston, et al.
Published: (2024-12-01)

Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
by: José Luis Huerta, et al.
Published: (2025-01-01)

Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice
by: Jie Shi, et al.
Published: (2025-08-01)

Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
by: Kumar Ilangovan, et al.
Published: (2025-08-01)

[Complementary Strategy of RSVpreF Vaccination/Nirsevimab versus Nirsevimab Alone for the Prevention of RSV Infection in Infants in Italy: A Cost-Minimization Analysis]
by: Giorgio Lorenzo Colombo, et al.
Published: (2025-07-01)

Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
by: Kosaku Komiya, et al.
Published: (2025-07-01)

Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain
by: Javier Álvarez Aldean, et al.
Published: (2024-05-01)

Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
by: Natalia Castillo Almeida, et al.
Published: (2025-03-01)

In Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor
by: Lars Radke, et al.
Published: (2017-08-01)

An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease
by: Min Lin, et al.
Published: (2022-09-01)

Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin American countries
by: Ru Han, et al.
Published: (2025-12-01)

Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia
by: Ru Han, et al.
Published: (2025-12-01)

RSV disease in infants and young children: Can we see a brighter future?
by: Eugenio Baraldi, et al.
Published: (2022-11-01)

Protective or limited? Maternal antibodies and RSV-associated lower respiratory tract infection in hospitalized infants aged 28-90 days
by: Shuanglian Li, et al.
Published: (2025-01-01)

Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
by: Pius I. Babawale, et al.
Published: (2025-01-01)

Molecular Mimicry between Respiratory Syncytial Virus F Antigen and the Human Proteome
by: Darja Kanduc
Published: (2023-01-01)

Public health impact of adjuvanted RSVPreF3 vaccine in older adults: a modeling study in nine countries in Middle East and North Africa
by: Evelina Zimovetz, et al.
Published: (2025-12-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020
by: Prince Mabilo, et al.
Published: (2022-10-01)

The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease
by: Gengxin Zhang, et al.
Published: (2024-10-01)

The RSV F p27 peptide: current knowledge, important questions
by: Wanderson Rezende, et al.
Published: (2023-06-01)

RSV awareness, risk perception, causes, and terms: Comment
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

Assessing the protection elicited by virus-like particles expressing the RSV pre-fusion F and tandem repeated G proteins against RSV rA2 line19F infection in mice
by: Min-Ju Kim, et al.
Published: (2024-01-01)

Epidemiological and Clinical Characteristics of Adult RSV Infections: A Retrospective Analysis at University Hospital Center Zagreb (2022–2024)
by: Antonio Perčinić, et al.
Published: (2025-03-01)

RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera
by: Cassandra A. L. Simonich, et al.
Published: (2025-07-01)

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
by: Sathya N. Thulasi Raman, et al.
Published: (2023-12-01)

Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysisResearch in context
by: Daira Trusinska, et al.
Published: (2025-06-01)

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
by: Antonios O. Aliprantis, et al.
Published: (2021-05-01)

Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity
by: Anna Condemi, et al.
Published: (2025-07-01)

Xuanfei Formula inhibited RSV infection by normalizing the SREBP2-mediated cholesterol synthesis process
by: Huan Qin, et al.
Published: (2024-05-01)

IFN-γ Attenuates Eosinophilic Inflammation but Is Not Essential for Protection against RSV-Enhanced Asthmatic Comorbidity in Adult Mice
by: Abenaya Muralidharan, et al.
Published: (2022-01-01)

RSV infection in Istanbul: risk factors and frequency
by: Elif İzci Güllü, et al.
Published: (2017-09-01)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
by: Harrison C. Bergeron, et al.
Published: (2022-10-01)

Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians
by: Matteo Riccò, et al.
Published: (2023-02-01)